Literature DB >> 31737199

miR-625-3p promotes migration and invasion and reduces apoptosis of clear cell renal cell carcinoma.

Liwen Zhao1, Kaihao Liu1, Xiang Pan1, Jing Quan1, Liang Zhou2, Zuwei Li3, Canbin Lin3, Jinling Xu1, Weijie Xu1, Xin Guan1, Hang Li1, Liangchao Ni1, Yaoting Gui1, Yongqing Lai1.   

Abstract

Clear cell renal cell carcinoma (ccRCC) is a common malignancy, yet, the mechanisms underlying tumorigenesis remain unclear. Several miRNAs have been implicated in the development of RCC previously via regulation of target gene expression. As miR-625-3p has recently been identified to play a role in development of other malignancies and is reportedly upregulated in ccRCC, we sought to investigate the role of this miRNA in the progression of ccRCC. Analysis of 30 paired fresh ccRCC tissues and adjacent normal renal tissues revealed that the expression of miR-625-3p was increased in ccRCC tissues compared to normal tissues. Subsequently, in 136 formalin-fixed paraffin-embedded ccRCC tissues, the increased miR-625-3p expression was correlated with poor prognosis for ccRCC patients. The diagnostic value of miR-625-3p was identified in 50 ccRCC patients and 74 healthy controls by ROC curve. miR-625-3p was decreased in serum of ccRCC patients compared to healthy individuals. miR-625-3p could serve as a promising serum biomarker for yielding an area under the receiver operating characteristic curve of 0.792 with 70.3% sensitivity and 80.0% specificity in discriminating ccRCC from healthy individuals. Using in vitro functional assays, we found that overexpression of miR-625-3p promoted migration and invasion of ccRCC cells but reduced ccRCC cell apoptosis. Inhibition of miR-625-3p, on the other hand, exerted the opposite effects. Bioinformatic analyses indicated that predicted gene targets of miR-625-3p are correlated with lower overall survival of ccRCC patients. Together, these findings demonstrate that miR-625-3p promotes ccRCC migration and invasion and reduces apoptosis, providing a prognostic marker for survival and a potential diagnostic and therapeutic target against ccRCC. AJTR
Copyright © 2019.

Entities:  

Keywords:  Renal cell carcinoma; biomarker; diagnosis; miR-625-3p; prognosis; progression

Year:  2019        PMID: 31737199      PMCID: PMC6834509     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  30 in total

1.  miR-206 functions as a novel cell cycle regulator and tumor suppressor in clear-cell renal cell carcinoma.

Authors:  Haibing Xiao; Wei Xiao; Jing Cao; Heng Li; Wei Guan; Xiaolin Guo; Ke Chen; Tao Zheng; Zhangqun Ye; Ji Wang; Hua Xu
Journal:  Cancer Lett       Date:  2016-01-22       Impact factor: 8.679

2.  Cellular disposal of miR23b by RAB27-dependent exosome release is linked to acquisition of metastatic properties.

Authors:  Marie Stampe Ostenfeld; Dennis K Jeppesen; Jens R Laurberg; Anders T Boysen; Jesper B Bramsen; Bjarke Primdal-Bengtson; An Hendrix; Philippe Lamy; Frederik Dagnaes-Hansen; Mads H Rasmussen; Khan H Bui; Niels Fristrup; Erik I Christensen; Iver Nordentoft; Jens P Morth; Jørgen B Jensen; Jakob S Pedersen; Martin Beck; Dan Theodorescu; Michael Borre; Kenneth A Howard; Lars Dyrskjøt; Torben Falck Ørntoft
Journal:  Cancer Res       Date:  2014-09-26       Impact factor: 12.701

3.  miR-122 promotes metastasis of clear-cell renal cell carcinoma by downregulating Dicer.

Authors:  Yang Fan; Xin Ma; Hongzhao Li; Yu Gao; Qingbo Huang; Yu Zhang; Xu Bao; Qingshan Du; Guoxiong Luo; Kan Liu; Qingyu Meng; Chaofei Zhao; Xu Zhang
Journal:  Int J Cancer       Date:  2017-11-08       Impact factor: 7.396

4.  MicroRNA-625-3p promotes cell migration of oral squamous cell carcinoma by regulating SCAI expression.

Authors:  D Xu; M Gu; H-L Liu
Journal:  Eur Rev Med Pharmacol Sci       Date:  2019-01       Impact factor: 3.507

5.  High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer.

Authors:  Mads H Rasmussen; Niels F Jensen; Line S Tarpgaard; Camilla Qvortrup; Maria U Rømer; Jan Stenvang; Tine P Hansen; Lise L Christensen; Jan Lindebjerg; Flemming Hansen; Benny V Jensen; Torben F Hansen; Per Pfeiffer; Nils Brünner; Torben F Ørntoft; Claus L Andersen
Journal:  Mol Oncol       Date:  2013-02-28       Impact factor: 6.603

Review 6.  Adjuvant therapy in renal cell carcinoma.

Authors:  Francesco Massari; Vincenzo Di Nunno; Chiara Ciccarese; Jeffrey Graham; Camillo Porta; Francesca Comito; Marta Cubelli; Roberto Iacovelli; Daniel Y C Heng
Journal:  Cancer Treat Rev       Date:  2017-09-23       Impact factor: 12.111

7.  miR-141 is a key regulator of renal cell carcinoma proliferation and metastasis by controlling EphA2 expression.

Authors:  Xuanyu Chen; Xuegang Wang; Anming Ruan; Weiwei Han; Yan Zhao; Xing Lu; Pei Xiao; Hangchuan Shi; Rong Wang; Li Chen; Shaoyong Chen; Quansheng Du; Hongmei Yang; Xiaoping Zhang
Journal:  Clin Cancer Res       Date:  2014-03-19       Impact factor: 12.531

8.  MiR-625-3p promotes cell migration and invasion via inhibition of SCAI in colorectal carcinoma cells.

Authors:  Hailun Zheng; Renqiang Ma; Qizhi Wang; Pei Zhang; Dapeng Li; Qiangwu Wang; Jianchao Wang; Huabin Li; Hao Liu; Zhiwei Wang
Journal:  Oncotarget       Date:  2015-09-29

9.  miR-143-3p inhibits the proliferation, migration and invasion in osteosarcoma by targeting FOSL2.

Authors:  Xiangran Sun; Guo Dai; Ling Yu; Qingzhu Hu; Jingteng Chen; Weichun Guo
Journal:  Sci Rep       Date:  2018-01-12       Impact factor: 4.379

10.  Expression of miR-652-3p and Effect on Apoptosis and Drug Sensitivity in Pediatric Acute Lymphoblastic Leukemia.

Authors:  Qian Jiang; Xiaojing Lu; Pengli Huang; Chao Gao; Xiaoxi Zhao; Tianyu Xing; Gang Li; Shilai Bao; Huyong Zheng
Journal:  Biomed Res Int       Date:  2018-06-05       Impact factor: 3.411

View more
  3 in total

1.  Exosomal mir-625-3p derived from hypoxic lung cancer cells facilitates metastasis by targeting SCAI.

Authors:  Yi Zhang; Kun Qian; Xingsheng Liu; Xin Zhao; Teng Zhao; Gaojun Lu
Journal:  Mol Biol Rep       Date:  2022-08-21       Impact factor: 2.742

2.  Systematic Analysis of microRNA Biomarkers for Diagnosis, Prognosis, and Therapy in Patients With Clear Cell Renal Cell Carcinoma.

Authors:  Guiyun Cheng; Mengru Li; Xiaoyu Ma; Fangmei Nan; Lu Zhang; Zhongyi Yan; Huimin Li; Guosen Zhang; Yali Han; Longxiang Xie; Xiangqian Guo
Journal:  Front Oncol       Date:  2020-12-04       Impact factor: 6.244

Review 3.  Circulating RNA in Kidney Cancer: What We Know and What We Still Suppose.

Authors:  Alessandra Cinque; Riccardo Vago; Francesco Trevisani
Journal:  Genes (Basel)       Date:  2021-05-28       Impact factor: 4.096

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.